OELKE MATHIAS 4
4 · NexImmune, Inc. · Filed Apr 7, 2022
Insider Transaction Report
Form 4
NexImmune, Inc.NEXI
OELKE MATHIAS
Chief Science Officer
Transactions
- Award
Stock Option (Right to Buy)
2022-04-05+60,000→ 60,000 totalExercise: $4.22Exp: 2032-04-04→ Common Stock (60,000 underlying)
Footnotes (1)
- [F1]25% of this option shall vest and become exercisable on April 5, 2023, with the remainder vesting in 36 equal monthly installments thereafter, subject to Mr. Oelke's continued service to the corporation on each vesting date.